Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31570490 | 1.00 | CYP3A4 (0.46) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL24892594 | 0.83 | KDM4E (0.34) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL30211607 | 0.83 | KDM4E (0.34) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL29202433 | 0.83 | KDM4E (0.34) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL24892479 | 0.82 | KDM4E (0.39) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL21114127 | 0.79 | KDM4E (0.36) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL25434269 | 0.78 | ALDH1A1 (0.35) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL2180477 | 0.75 | CYP3A4 (0.67) | CYP3A4KDM4ECYP1A2MAPTCYP2C9 | |
| SCHEMBL24206970 | 0.74 | LIPG (0.43) | LPLLIPG | |
| SCHEMBL28574968 | 0.74 | LPL (0.40) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2023287793-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| WO-2019136314-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119740-A1 | THERAPEUTIC COMPOUNDS AND METHODS | PCK1, SLC5A1, PFKFB1 | CYP3A4 384/4885KDM4E 1568/4885CYP1A2 680/4885 |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | CYP3A4 2367/4885KDM4E 4784/4885CYP1A2 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.